التفاصيل البيبلوغرافية
| العنوان: |
Routine Induction Therapy in Living Donor Liver Transplantation Prevents Rejection but May Promote Recurrence of Hepatitis C |
| المؤلفون: |
Ghanekar, A. anand.ghanekar@uhn.ca, Kashfi, A.1, Cattral, M.1, Selzner, N.1, McGilvray, I.1, Selzner, M.1, Renner, E.1, Lilly, L.1, Levy, G.1, Grant, D.1, Greig, P.1 |
| المصدر: |
Transplantation Proceedings. Jun2012, Vol. 44 Issue 5, p1351-1356. 6p. |
| مصطلحات موضوعية: |
*ORGAN donors, *LIVER transplantation, *GRAFT rejection, *HEPATITIS C, *DISEASE relapse, *BASILIXIMAB |
| مستخلص: |
Abstract: Background: Routine induction therapy in living donor liver transplantation (LDLT) has not been well described. Methods: We reviewed outcomes of induction therapy with rabbit antithymocyte globulin (rATG) or basiliximab within 1 year of LDLT. Results: Between 2002 and 2007, 184 adults underwent LDLT and received induction therapy in addition to standard immunosuppression. Acute cellular rejection (ACR) developed in 17 of 130 patients (13.1%) who received rATG and 13 of 54 patients (24.1%) who received basiliximab (P = .066). The interval between transplantation and rejection as well as rejection severity was similar in patients who received rATG and those who received basiliximab. Hepatitis C (HCV) recurrence requiring initiation of antiviral therapy was more common in patients who received rATG compared with basiliximab (34.5% vs 8.7%; P = .021), and in those who received induction combined with tacrolimus as opposed to cyclosporine (38.5% vs 3.9%; P = .001). rATG and basiliximab were associated with excellent patient and graft survivals well as low rates of opportunistic infections and malignancies. Conclusion: Induction with rATG or basiliximab was well tolerated and highly effective at preventing ACR within 1 year of LDLT, but may be associated with a higher risk of clinically significant HCV recurrence in some patients. [Copyright &y& Elsevier] |
| قاعدة البيانات: |
Academic Search Index |
